LB Pharmaceuticals initiates coverage with buy rating; target price $68
LBRX•Needham initiated coverage of LB Pharmaceuticals with a buy rating and a $68 target price.
Related News
European shares rebound ahead of euro zone inflation data, US jobs report
VGK•
Major drugmakers turn to China for licensing deals
NVS•
Edison International: Jefferies cuts to underperform from hold; cuts target price to $42 from $53
EIX•
Kazakhstan's September oil and gas condensate output falls 7% from August
USO•
Fair Isaac cuts target price to $875 from $935
FICO•